A Phase I Study Of The Vascular Disrupting Combretastatin, OXi4503, In Patients With Relapsed and Refractory Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS)Daniel Turner, Christopher R. Cogle, Elizabeth Wise et al.|Blood|2013Cited by 12
A Phase I Study of the Vascular Disrupting Combretastatin, OXi4503, in Patients with Relapsed and Refractory Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS)Christopher R. Cogle, John R. Wingard, Andrés González et al.|Blood|2012Cited by 0